Altimmune, Inc. announced Impairment loss on intangible asset of $12.4 million was recognized during the three months ended December 31, 2023 related to the acquired In-Process Research and Development asset associated with HepTcell. The overall response in the Phase 2 trial was deemed to be insufficient to warrant further advancement. As a result, any further development related to HepTcell has been stopped.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.6 USD | -2.08% |
|
+3.37% | -41.33% |
Jul. 01 | Altimmune, Inc.(NasdaqGM:ALT) added to Russell 3000 Growth Index | CI |
Jul. 01 | Altimmune, Inc.(NasdaqGM:ALT) added to Russell Microcap Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.33% | 468M | |
+15.58% | 121B | |
+16.60% | 110B | |
+18.46% | 25.98B | |
-24.33% | 19.27B | |
-18.38% | 15.99B | |
-17.95% | 15.66B | |
-48.32% | 14.5B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023